ADC Therapeutics SA (ADCT) Stock Analysis & AI Equity Report
ADC Therapeutics SA (ADCT) overview
ADC Therapeutics SA (ADCT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 81.4m and operating profit of USD -121m; the year-end share price was 3.53 USD and market capitalisation was USD 444m. ADC Therapeutics SA is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ADC Therapeutics SA's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About ADC Therapeutics SA
ADC Therapeutics develops and commercializes antibody drug conjugate medicines. Its portfolio includes ZYNLONTA, a CD19-directed therapy approved for certain patients with relapsed or refractory diffuse large B-cell lymphoma. The company also conducts clinical trials studying the medicine in combinations, earlier treatment lines and indolent lymphomas. Its operations include clinical development, manufacturing capabilities and commercialization, supported by an external contract manufacturing network.
Generate the ADC Therapeutics SA report
ADC Therapeutics SA is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for ADC Therapeutics SA and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on ADC Therapeutics SA
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.